Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafasitamab, Lenalidomide and Venetoclax in R/R MCL
NCT05910801Phase 2Recruiting
- Sponsor
- Academic and Community Cancer Research United
- Start
- Jan 2024
- Primary completion
- Dec 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tafasitamab in mantle cell lymphoma (MCL), sponsored by Academic and Community Cancer Research United. Started Jan 2024; status: recruiting.
02
Drugs
tafasitamab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT05910801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05910801.